Effects of synthetic oligonucleotides on human complement and coagulation∗

This publication has 21 references indexed in Scilit:

• Antisense oligonucleotides: towards clinical trials
  Trends in Biotechnology, 1996
• Modified oligonucleotides as therapeutic and diagnostic agents
  Current Opinion in Biotechnology, 1995
• Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration
  Biochemical Pharmacology, 1995
• In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats
  Biochemical Pharmacology, 1995
• Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects*
  Clinical Pharmacology & Therapeutics, 1995
• Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1
  Biochemical Pharmacology, 1995
• Pharmacokinetics of Antisense Oligonucleotides
  Clinical Pharmacokinetics, 1995
• Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-o- methyloligoribonucleotides
  Bioorganic & Medicinal Chemistry Letters, 1994
• Pharmacokinetics of an Antisense Phosphorothioate Oligodeoxynucleotide againstrevfrom Human Immunodeficiency Virus Type 1 in the Adult Male Rat Following Single Injections and Continuous Infusion
  Antisense Research and Development, 1994
• Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity
  Nucleic Acids Research, 1993